⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807732 | 0.81 | — | — | |
| SCHEMBL4269628 | 0.81 | — | — | |
| SCHEMBL16637592 | 0.79 | CYP1A2 (0.34) | — | |
| SCHEMBL19413114 | 0.79 | GOT1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL31617543 | 0.79 | GOT1 (0.37) | — | |
| SCHEMBL23119168 | 0.79 | GOT1 (0.37) | — | |
| SCHEMBL22023659 | 0.79 | GOT1 (0.37) | — | |
| SCHEMBL21166276 | 0.77 | — | — | |
| SCHEMBL6241867 | 0.77 | — | — | |
| SCHEMBL22849136 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| WO-2024238570-A1 | CDK2 INHIBITOR PYRAZOLOPYRIMIDINE COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240368133-A1 | Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling | CONFO THERAPEUTICS N.V. (BE) | 2024-11-07 | — | — | US | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4377307-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | Confo Therapeutics N.V. (BE) | 2024-06-05 | — | — | EP | disclosed |
| EP-4363423-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-5665763-A | ANTIPICORNAVIRAL AGENTS | SANOFI, S.A. (FR) | 1997-09-09 | — | — | US | disclosed |
| US-5567717-A | COMBATTING PICORNAVIRUSES | STERLING WINTHROP, INC. (US) | 1996-10-22 | — | — | US | disclosed |
| US-5514679-A | TREATMENT OF PICORNAVIRUS INFECTIONS | STERLING WINTHROP INC. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995031439-A1 | THERAPEUTIC PHENOXYALKYLPYRIDAZINES AND INTERMEDIATES THEREFOR | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0475214-B1 | Caffeic acid derivatives and pharmaceutical compositions containing the same | SUNTORY LTD (JP) | 1995-06-07 | — | — | EP | disclosed |
| US-5326785-A | Arteriosclerosis andn diseases of the circulatory system | SUNTORY LIMITED (JP) | 1994-07-05 | — | — | US | disclosed |
| US-5232941-A | Therapeutic agents for diseases of the circulatory system | SUNTORY LIMITED (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0475214-A1 | Caffeic acid derivatives and pharmaceutical compositions containing the same | SUNTORY LIMITED (JP) | 1992-03-18 | — | — | EP | disclosed |